Company
Hq Spclt Pharma
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
9
8 still marketed
Novel approvals
2
Approvals since 2021
4
Originals and new uses
Phase 3 trials
0
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Cefazolin Sodium new use Feb 13, 2026
- Diltiazem Hydrochloride In 0.72% Sodium Chloride approved Feb 21, 2025
- Meropenem approved Jul 26, 2023
- Cefazolin Sodium approved May 8, 2023
- Calcium Gluconate approved Oct 29, 2018
- Dexmedetomidine Hydrochloride new use Sep 19, 2016
- Esmolol Hydrochloride Double Strength In Plastic Container approved Apr 7, 2016
- Dexmedetomidine Hydrochloride approved Oct 21, 2015
- Levetiracetam In Sodium Chloride approved Nov 9, 2011
- Taxol new use Priority reviewJun 20, 2000
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
No recruiting Phase 3 trials under this sponsor name.
Marketed drugs (8)
Newest FDA action first.
- Meropenem Meropenem · 2023
- Dexmedetomidine Hydrochloride Dexmedetomidine Hydrochloride · 2015
- Cefazolin Sodium Cefazolin Sodium · 2023
- Diltiazem Hydrochloride In 0.72% Sodium Chloride Diltiazem Hydrochloride · 2025
- Esmolol Hydrochloride Double Strength In Plastic Container Esmolol Hydrochloride · 2016
- Levetiracetam In Sodium Chloride Levetiracetam · 2011
- Platinol-Aq Cisplatin · 1978
- Calcium Gluconate Calcium Gluconate · 2018
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.